DALLAS, April 29, 2013 /PRNewswire-iReach/ -- "The Pharmaceutical Market: Norway," "The Pharmaceutical Market: Austria," "The Pharmaceutical Market: Belgium," "The Pharmaceutical Market: Ireland," "The Pharmaceutical Market: Denmark," "The Pharmaceutical Market: Finland" and "The Pharmaceutical Market: Cuba" are new reports available at RnR Market Research reports library.
The competitive landscape info on the pharmaceutical market in Austria, Norway, Denmark, Belgium, Cuba, Finland & Ireland covers comparative company analyses and rankings by US$ sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors in each country.
The macro environment for the Finnish pharmaceutical industry is improving. Demographically, Finland has one of the largest proportions of population over the age of 65 in Western Europe. Latest projections expect that the population aged 65 and over will constitute more than one-fifth of the total population by 2017. There are three leading domestic producers in Finland; Orion, Verman and Vitabalans. Multinational companies Bayer and Santen also have production facilities in Finland. The top ten pharmaceutical companies in Finland had combined sales of over 1.0 billion euros at wholesale prices in 2010, equal to a share of over half of the market. The leading company was Orion, with a market share of nearly 10.0%. This was followed by Pfizer, Novartis, AstraZeneca and GlaxoSmithKline. In the biologic sector, Biotie Therapies completed its acquisition of Synosia Therapeutics in February 2011, while Ark Therapeutics entered into a formal agreement to divest the majority of its woundcare business in the same month. Complete report @ http://www.rnrmarketresearch.com/the-pharmaceutical-market-finland-market-report.html.
The increasing pharmaceutical expenditure in Denmark has led to price freezes and caps in recent years. The savings made have been more than counterbalanced by the wider use of new and expensive pharmaceuticals, which are required to ensure the most effective treatment. This is especially true in areas such as hypertension, high cholesterol and so on, where many new therapies have become available recently. With Denmark pharmaceutical market having strong domestic production, many producers focus on the export market. Due to the presence of Novo Nordisk, Denmark is a major global supplier of insulin in retail form. In August 2011, Novo Nordisk announced it is planning to build two new office buildings in Bagsværd. Previously, in June 2011, the company announced it is to invest in a new plant in Kalundborg, for the production of biopharmaceuticals. Complete report @ http://www.rnrmarketresearch.com/the-pharmaceutical-market-denmark-market-report.html.
The Cuban pharmaceutical market is the smallest in the Americas region. Espicom projects a moderate CAGR in dollar terms between 2011 and 2016. The Cuban pharmaceutical market increased in value by five times in the 1995-2010 period.
Cardiovascular drugs are leaders in the Austrian pharmaceutical market, both in terms of value and volume. Other leading therapeutic areas in terms of value are the nervous system, antineoplastic & immunomodulating agents and alimentary tract & metabolism. In terms of volume, other leading therapeutic areas are the alimentary tract & metabolism, the nervous system and the musculoskeletal system. Meanwhile, the leading OTC product group is cough & cold remedies, followed by vitamins & minerals, pain relievers and stomach & digestion products. Several multinational pharmaceutical companies have production sites in Austria, including Baxter, Boehringer Ingelheim, Fresenius Kabi, Nycomed and Sandoz. Aside from these, there are also a number of small- and medium-sized pharmaceutical companies, as well as several research-based companies. Complete report @ http://www.rnrmarketresearch.com/the-pharmaceutical-market-austria-market-report.html.
Most global companies have some manufacturing presence in the pharmaceutical market in Ireland. Drugs are either produced in finished form for export, or exported on to other facilities for finishing. A number of branded drugs go off patent in 2012, including Pfizer's Lipitor and Eli Lilly's Zyprexa, which could have a negative impact on the industry. However, several multinational companies have been moving into the biologic sector in preparation for the loss of profit from these blockbuster drugs. While the multinational presence is very strong, Ireland has very few domestic producers. In September 2011, Alkermes completed its merger with Elan Drug Technologies (EDT) to form a new company, Alkermes Plc., which is headquartered in Dublin. In September 2011, Pfizer announced it was to invest US$200.0 million at its Grange Castle site, to add two processing suites and to expand current production and product testing capabilities. In September 2011, MSD opened its new R&D centre at its Ballydine site, creating 70 new jobs. Previously, in June 2011, MSD opened two new facilities at the site in Brinny. Complete report @ http://www.rnrmarketresearch.com/the-pharmaceutical-market-ireland-market-report.html.
Explore more reports on the Pharmaceutical Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals.
RnRMarketResearch.com (http://www.rnrmarketresearch.com/) is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. Explore our blog @ http://www.rnrmarketresearch.com/blog/.
Browse company profiles and SWOT analysis reports for thousands of companies @ http://www.rnrcompanyprofiles.com/.
Media Contact: Priyank Tiwari RnR Market Research, +1 888 391 5441, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
|SOURCE RnR Market Research|
Copyright©2012 PR Newswire.
All rights reserved